Navigation Links
Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
Date:11/12/2013

DURHAM, N.C., Nov. 12, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeff Abbey, president and chief executive officer, is scheduled to present at the Elsevier Therapeutic Area Partnerships Meeting on November 19 at the Hyatt Regency Boston. Event:

Elsevier Therapeutic Area Partnerships MeetingDate:

Tuesday, November 19, 2013Time:

2:55 PMLocation: 

Duxbury Room, 4th FloorHyatt Regency Boston1 Avenue De Lafayette, Boston, MA 02111Mr. Abbey will present an overview of the clinical development program for the Company's investigational fully personalized immunotherapy targeted to HIV, AGS-004, which has been designated as one of the "Top Projects to Watch" in infectious disease at the meeting. 

About the Arcelis™ Technology PlatformArcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos TherapeuticsArgos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.  Argos' most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV. For more information about Argos Therapeutics, visit www.argostherapeutics.com.


'/>"/>
SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
2. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
5. Sorrento Therapeutics Adopts Stockholder Rights Plan
6. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
7. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
8. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
9. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
10. Echo Therapeutics Announces Third Quarter 2013 Financial Results
11. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016 Research ... for PET Imaging in the USA"  report to their ... provides information on the current Positron Emission Tomography (PET) ... USA market. Along with the current known ... USA , the report also contains a ...
(Date:5/5/2016)... Research and Markets has ... Market and Competitive Landscape Highlights - 2016" ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) The ... Landscape Highlights - 2016, provides comprehensive insights ... market valuations and forecast, Thalassaemia products sales ...
(Date:5/4/2016)... Calif. , May 4, 2016  It,s time for an upgrade. There are ... on a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity ... as well as a world class manufacturer of innovative technology.  Photo - ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... VisualDx ... devices. VisualDx is the first point of care diagnostic support system to ... The system speeds diagnosis, therapy decisions and patient education for emergency physicians, ...
(Date:5/5/2016)... ... ... summer is just around the corner. Summer means a lot of different things to people. ... play all day and night. Parents often lament the coming of summer as they will ... means trips to the beach, backyard cookouts, fireworks on the Fourth of July, and even ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 ... and up 27 percent since 2012. , The results of the 2015 ASDS Survey ... increase in skin cancer treatments and the growing popularity of soft-tissue fillers and body ...
(Date:5/5/2016)... Washington, DC (PRWEB) , ... ... ... Contact: Claudia Tellez, Executive Director 703.462.0658, ctellez(at)msnva.org , The Medical Society of ... community physicians and their patients , The Medical Society of Northern Virginia ...
(Date:5/5/2016)... ... , ... Nepenthe Laboratory Services (NLS), a premier drug monitoring and toxicology laboratory, ... item donations for Food for Lane County, and to help support awareness for the ... the assembly was to create an exciting atmosphere for the kids at Riverbend to ...
Breaking Medicine News(10 mins):